Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on Arthritis and children: What is JIA?
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis affecting children and adolescents under the age of 16. It is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, leading to inflammation in the joints. This results in symptoms such as joint pain, swelling, stiffness, and reduced mobility. JIA can affect one or multiple joints and, in some cases, may also involve other organs, such as the eyes or skin.
There are several subtypes of JIA, each with different characteristics and levels of severity. While the exact cause is unknown, a combination of genetic and environmental factors is believed to play a role. Early diagnosis and treatment are crucial in managing JIA, as they can prevent long-term joint damage and improve the child’s quality of life. Treatment typically includes medications like NSAIDs, DMARDs, or biologics, along with physical therapy to maintain joint function and mobility.
Therefore, get an overall knowledge of arthritis and children: what is JIA?
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation